A number of biotechnology stocks closed lower in Tuesday'sweak market, which saw the Dow fall 45-and-a-half points.

Regeneron (NASDAQ:REGN) closed at $16, down $1.63. The stockhas fallen steadily since its initial public offering was priced at$22 last week, and is trading at the low end of the price rangeproposed when the IPO was announced in February.

Genzyme (NASDAQ:GENZ) fell $1.88, closing at $36.63. OnMonday, Genzyme announced it had received Food and DrugAdministration approval for Ceredase to treat Type 1 Gaucher'sdisease. The orphan drug is the company's first biotherapeuticproduct.

Investors took profits in Agouron (NASDAQ:AGPH), whichclosed at $17.75, down $2.63. Agouron stock had gained 99percent in the previous two trading sessions after the companyreported that it had determined the three-dimensionalstructure of reverse transcriptase, an enzyme critical forreplicating the AIDS virus.

(c) 1997 American Health Consultants. All rights reserved.